ATLANTA, Aug. 27, 2018 /PRNewswire/ -- Rimidi, a digital health company that provides software and clinical analytics for chronic disease management, today announced that Jim Clifford has joined the company as Vice President of Strategic Sales.
"Jim's joining Rimidi is a great win for the company and for our clients. Jim's depth of experience and knowledge of HIT will bring enormous value. With our current growth in the market, having someone of Jim's caliber lead the sales team is a huge asset for us. His passion for improving patient outcomes through technology will inspire our clients and provider communities," says Josh Claman, Rimidi's CEO.
Jim Clifford has over 22 years of experience in HIT. Clifford spent 10 years with MEDITECH, working in many facets of HIT including sales. A founding member of the Wellcentive team, he was instrumental to the growth and success of the company. He worked in every sector of the company including implementation, user training, project management, product design and consulting. Most recently, Clifford held the role of Strategic Sales Director for Philips Wellcentive, in which he focused on sales and business development.
"What attracted me to Rimidi is that the platform represents and leads the next great step in HIT, that of physician and patient engagement," says Clifford. "What captured me was seeing the way that Rimidi brings clinical expertise, remote monitoring and vastly improved connectivity to the patient-doctor relationship. Rimidi actually makes IT work for the clinician and improves workflow, making time spent with the patient more efficient, impactful and more focused on the patient."
Rimidi recently raised a $6.7 million Series A-1 round, with a strategic investment by Eli Lilly & Co. (LLY).
Rimidi is an Atlanta-based, digital health company bringing to market data analytics and disease management solutions. Its flagship product, Rimidi | Diabetes, is a software solution focused on empowering quality diabetes care for healthcare organizations, providers, and people living with diabetes. Rimidi has expanded its platform to heart failure and fatty liver disease this year and will continue to expand into other cardio-metabolic diseases. For more information, visit Rimidi-Serious Hope for Healthcare